Great news! 🎉 Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate. 🔗Read the press release here: dndi.org/press-releas...

Today, @griffen-ed.bsky.social explains at the Open Drug Discovery Symposium how @asapdiscovery.bsky.social has developed a hybrid intellectual property model that counterintuitively uses patents to support open science innovation and ensure affordability & global access. 🔗 shorturl.at/gMY0t

'We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that.' Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️ cen.acs.org/pharmaceutic...

At #ACSSpring2025, Ed Griffen of MedChemica disclosed the structure of a pancoronavirus antiviral that targets the main protease of the two different coronaviruses that cause Middle East respiratory syndrome (MERS) and COVID-19. cen.acs.org/acs-news/acs... 🧪

📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)

If you missed previous Antiviral Drug Discovery Open Science Forum talks, you can find videos of all of them online here: asapdiscovery.org/forum/#past-...

The COVID-Moonshot is an open-science, crowdsourced drug discovery initiative working to develop a straight-to-generic, accessible, and affordable #COVID19 antiviral. Learn more: www.science.org/doi/10.1126/...